Jesse's Journey Foundation
Defeat Duchenne. Change Lives.

News & Resources

Jesse’s Journey and PPPMD Award Clinical Fellowship in Duchenne Endocrinology and Bone Fragility

June 16, 2021

Jesse's Journey and Parent Project Muscular Dystrophy Award $172,000 (CAD) Clinical Fellowship in Duchenne Endocrinology and Bone Fragility. Award Will Sponsor a Two-Year Fellowship Under Dr. Leanne Ward, the University of Ottawa with Focus on Endocrine and Bone Complications of Duchenne. Parent Project Muscular Dystrophy (PPMD), a US nonprofit organization leading the fight to end [...]
Continue Reading

Santhera and ReveraGen: Positive Topline Results with Vamorolone in VISION-DMD Study

June 1, 2021

Santhera and ReveraGen have announced positive topline results for vamorolone, a steroid alternative for individuals living with Duchenne muscular dystrophy (DMD). Their pivotal VISION-DMD study in boys 4 to <7 years old demonstrated benefits across multiply timed tests compared to placebo (boys not on treatment) and similar benefits to individuals taking prednisone. Vamorolone also showed [...]
Continue Reading

Solid Biosciences: IGNITE DMD Phase I/II Clinical Trial Update

May 20, 2021

Jesse’s Journey is pleased to share the letter for the Duchenne community from Solid Biosciences, providing a business update and including a dosing update in the IGNITE DMD Phase I/II clinical trial and promising long-term biopsy data from prior patients dosed with SGT-001 in the high dose cohort at 2E14 vg/kg. They also announced the [...]
Continue Reading

Pfizer: Canada Launches First Gene Therapy Trial for Duchenne

May 4, 2021

Ground-breaking news, Canada has launched the first gene therapy trial for Duchenne muscular dystrophy. Pfizer’s investigational gene therapy treatment is now recruiting in Canada at Children's Hospital - London Health Sciences Centre in London, Ontario. This is an international study and their first site to open in North America. Boys with a confirmed diagnosis of [...]
Continue Reading

Jesse’s Journey: Grants $1.7 million to Duchenne muscular dystrophy research

May 4, 2021

Jesse's Journey, Canada's leader in Duchenne muscular dystrophy funded research, is proud to announce that it will grant $1.7M toward four promising research projects this year - the largest annual amount in its 26-year history. Duchenne muscular dystrophy is a life-threatening, progressive, neuromuscular disorder with no cure. Affecting approximately 1 in every 5,000 boys in [...]
Continue Reading

Sarepta Therapeutics: SRP-9001 (ENDEAVOR) Gene Therapy Study Update

May 20, 2021

Jesse’s Journey is pleased to share an update from Sarepta Therapeutics on their Gene Therapy for DMD SRP-9001. The results from the first 11 patients enrolled showed an increase in micro-dystrophin expression and a consistent safety profile. “We are delighted by these seminal results from the ENDEAVOR Study, our first trial results with SRP-9001 made [...]
Continue Reading

World Duchenne Awareness Day: September 7, 2021

May 13, 2021

September 7 is World Duchenne Awareness Day. On this day, Jesse's Journey joins forces with organizations from around the world to raise awareness for Duchenne and Becker Muscular Dystrophy (DMD/BMD). Every year, the World Duchenne Organization sets a special theme to the day that that deserves more attention. This year it will be ‘Adult Life [...]
Continue Reading

Capricor Therapeutics: Expands its Exosome Platform Technology Portfolio

May 4, 2021

Capricor Therapeutics has announced that it has signed an exclusive, worldwide licensing agreement with Johns Hopkins University (JHU) to include engineered exosomes for vaccines and therapeutics as part of its exosome technology portfolio. Exosome-based therapy is an exciting area for Duchenne muscular dystrophy. We hope it will become the next generation of gene therapy without [...]
Continue Reading

Sarepta Therapeutics: Reports Positive Clinical Results from Phase 2 MOMENTUM Study of SRP-5051

May 4, 2021

Sarepta Therapeutics has announced encouraging results on their PPMO drug candidate for individuals with Duchenne muscular dystrophy amenable to Exon 51 skipping. Preliminary data for the 30mg/kg dose shows 6.55% mean dystrophin expression and predicting longer-term use will achieve greater than 10% dystrophin production. Hypomagnesemia was identified as a safety concern, but all cases are [...]
Continue Reading

Open Letter to Minister: Reduce the Timing Between Doses for Patients with Neuromuscular Diseases

April 29, 2021

The Honourable Patty Hajdu, P.C., M.P. Minister of Health Via email: Patty.Hajdu@parl.gc.ca Dear Minister Hajdu: We are a group of physicians, health care workers and stakeholders who care for patients with neuromuscular diseases across Canada. We are writing this open letter to request for patients with neuromuscular diseases to be eligible for vaccination doses earlier [...]
Continue Reading
Disclaimer: Jesse's Journey provides the above information as a potential resource for our visitors. We do not verify the accuracy or truth of third party information and cannot be responsible for the quality of the information or services provided by other organizations and mentioned on our website, nor do we endorse any service, product, treatment or therapy.

Recent News

Category